Discovery of Imidazo[1,2-<i>a</i>]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis
作者:Subramanyam J. Tantry、Shankar D. Markad、Vikas Shinde、Jyothi Bhat、Gayathri Balakrishnan、Amit K. Gupta、Anisha Ambady、Anandkumar Raichurkar、Chaitanyakumar Kedari、Sreevalli Sharma、Naina V. Mudugal、Ashwini Narayan、C. N. Naveen Kumar、Robert Nanduri、Sowmya Bharath、Jitendar Reddy、Vijender Panduga、K. R. Prabhakar、Karthikeyan Kandaswamy、Ramanatha Saralaya、Parvinder Kaur、Neela Dinesh、Supreeth Guptha、Kirsty Rich、David Murray、Helen Plant、Marian Preston、Helen Ashton、Darren Plant、Jarrod Walsh、Peter Alcock、Kathryn Naylor、Matthew Collier、James Whiteaker、Robert E. McLaughlin、Meenakshi Mallya、Manoranjan Panda、Suresh Rudrapatna、Vasanthi Ramachandran、Radha Shandil、Vasan K. Sambandamurthy、Khisi Mdluli、Christopher B. Cooper、Harvey Rubin、Takahiro Yano、Pravin Iyer、Shridhar Narayanan、Stefan Kavanagh、Kakoli Mukherjee、V. Balasubramanian、Vinayak P. Hosagrahara、Suresh Solapure、Sudha Ravishankar、Shahul Hameed P
DOI:10.1021/acs.jmedchem.6b01358
日期:2017.2.23
relationship of these two scaffolds, resulting in nanomolar potencies in an ATP synthesis inhibition assay. A biochemical deconvolution cascade suggested cytochrome c oxidase as the potential target of IPE class of molecules, whereas characterization of spontaneous resistant mutants of SQAs unambiguously identified ATP synthase as its molecular target. Absence of cross resistance against bedaquiline resistant
苯达喹啉用于治疗结核病的批准已证实三磷酸腺苷(ATP)合酶是杀死结核分枝杆菌(Mtb)的诱人靶标。在这里,我们报告发现了两个不同的铅系列咪唑[1,2- a]吡啶醚(IPE)和方酰胺(SQA)作为分枝杆菌ATP合成的抑制剂。通过药物化学探索,我们建立了这两个支架之间稳固的结构-活性关系,从而在ATP合成抑制试验中产生了纳摩尔浓度的效价。生化解卷积级联反应表明,细胞色素c氧化酶是IPE类分子的潜在靶标,而SQA自发抗性突变体的表征明确地确定了ATP合酶是其分子靶标。缺乏对苯达喹啉抗性突变体的交叉抗性表明,ATP合酶上SQA的结合位点不同。此外,SQA被发现是无细胞毒性的,并且在结核感染的小鼠模型中显示出功效。